Research Article
An Integrating Immune-Related Signature to Improve Prognosis of Hepatocellular Carcinoma
Table 1
Summary of HCC patients’ clinicopathological characteristics from TCGA database.
| Characteristics | Patient | Training set | Validation set | Sum | Amount | % | Amount | % | Amount | % |
| Age at diagnosis | | | | | | | ≥60 | 98 | 52.40 | 103 | 56.28 | 201 | 54.32 | <60 | 89 | 47.60 | 80 | 43.72 | 169 | 45.68 | Gender | | | | | | | Male | 133 | 71.12 | 116 | 63.39 | 249 | 67.30 | Female | 54 | 28.88 | 67 | 36.61 | 121 | 32.70 | Clinical stage | | | | | | | Stage I | 76 | 40.64 | 95 | 51.91 | 171 | 46.22 | Stage II | 45 | 24.07 | 40 | 21.85 | 85 | 22.97 | Stage III | 47 | 25.13 | 38 | 20.77 | 85 | 22.97 | Stage IV | 4 | 2.14 | 1 | 0.55 | 5 | 1.35 | Others/unknown | 15 | 8.02 | 9 | 4.92 | 24 | 6.49 | Tumor grade | | | | | | | G1 | 26 | 13.90 | 29 | 15.85 | 55 | 14.87 | G2 | 91 | 48.66 | 86 | 47.00 | 177 | 47.84 | G3 | 63 | 33.69 | 58 | 31.67 | 121 | 32.70 | G4 | 6 | 3.21 | 6 | 3.28 | 12 | 3.24 | Others/unknown | 1 | 0.54 | 4 | 2.20 | 5 | 1.35 | Survival status | | | | | | | Survive | 133 | 71.12 | 107 | 58.47 | 240 | 64.87 | Death | 54 | 28.88 | 76 | 41.53 | 130 | 35.13 |
|
|